Preliminary survival analysis of postoperative simultaneous radiochemotherapy with hyperthermia in glioblastoma patients
10.3760/cma.j.cn113030-20200914-00467
- VernacularTitle:胶质母细胞瘤术后热疗同步放化疗初步生存分析
- Author:
Jingyi ZHAO
1
;
Bingyan LI
;
Linhui CHEN
;
Tiansong LIANG
;
Yingjuan ZHENG
;
Daoke YANG
Author Information
1. 郑州大学第一附属医院放疗科 450052
- Keywords:
Glioblastoma/hyperthermia;
Glioblastoma/radiochemotherapy;
Survival time
- From:
Chinese Journal of Radiation Oncology
2021;30(9):888-891
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To initially investigate whether simultaneous radiochemotherapy with hyperthermia can prolong the survival of glioblastoma (GBM) patients.Methods:Clinical data of 61 GBM patients undergoing surgery in our hospital from September 2016 to June 2019 were retrospectively analyzed. According to different treatment methods, all patients were divided into the control group ( n=34) and observation group ( n=27). In the control group, three-dimensional radiotherapy with a dose of 60 Gy combined with temoazolamine chemotherapy was delivered. In the observation group, simultaneous radiochemotherapy with 15-20 cycles of hyperthermia at 40-41℃ was supplemented. The survival time was calculated by Kaplan-Meier method, and the survival time was compared with log-rank test between two groups. Results:The median progression-free survival in the observation group was significantly longer than that in the control group (14.33 months vs.9.94 months, P<0.05). The median overall survival in the observation group was also remarkably higher than that in the control group (18 months vs. 14 months, P<0.05). Conclusions:Simultaneous radiochemotherapy with hyperthermia is innovatively applied to treat GBM after surgical resection. Preliminary findings demonstrate that compared with chemoradiotherapy, simultaneous radiochemotherapy with hyperthermia can prolong the survival time of GBM patients.
